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Abstract  
 
Transglutaminases (TG) are externalized from cells via an unknown unconventional secretory 
pathway. We show for the first time that purinergic signaling regulates active secretion of TG2, an 
enzyme with a pivotal role in stabilizing extracellular matrices and modulating cell-matrix 
interactions in tissue repair. Extracellular ATP promotes TG2 secretion by macrophages, and this 
can be blocked by a purinergic receptor P2X7 (P2X7R)-selective antagonist. Introduction of 
functional P2X7R into HEK293 cells is sufficient to confer rapid, regulated TG2 export. By 
employing pharmacological agents, TG2 release could be separated from P2X7R-mediated 
microvesicle shedding. Neither, Ca2+ signaling alone nor membrane depolarization triggered TG2 
secretion which occurred only upon receptor membrane pore formation and without pannexin 
channel involvement. A gain-of-function mutation in P2X7R associated with autoimmune disease 
caused enhanced TG2 externalization from cells, and this correlated with increased pore activity. 
These results provide a mechanistic explanation for a link between active TG2 secretion and 
inflammatory responses, and aberrant enhanced TG2 activity in certain autoimmune conditions. 
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Introduction 
 
Unconventional export of cytoplasmic proteins, i.e. the processes by which proteins that do not 
follow the classical ER/Golgi secretory pathway are secreted by cells, is being studied extensively 
as many molecules that fall into this category constitute potent biological signals with key roles in 
developmental or inflammatory processes. Such proteins lack posttranslational modifications that 
occur during ER/Golgi protein maturation but may be subject to N-terminal processing and 
acetylation or acylation (Muesch et al., 1990; Stegmayer et al., 2005). Several fundamentally 
different mechanisms appear to support unconventional protein secretion including self-sustained or 
transporter-facilitated direct membrane translocation at the plasma membrane, or release in 
specialized vesicles, the biogenesis of which is distinct from coat protein complex II-coated vesicles 
(Nickel and Rabouille, 2009; Rabouille et al., 2012). Neither export through the compartment for 
unconventional protein secretion/multivesicular body pathway nor direct microvesicle (MV) 
shedding at the plasma membrane requires membrane translocation of the cargo, and release is 
thought to occur by vesicle lysis in the extracellular environment.  
 
Transglutaminases (TG) are a family of structurally similar enzymes that post-
translationally modify proteins through transamidation, deamidation or esterification of glutaminyl 
residues (Aeschlimann and Thomazy, 2000). Several of these enzymes have well established 
functions in stabilizing extracellular protein assemblies, including TG2 (wound healing), TG4 
(semen coagulation) and factor XIII (blood coagulation) (Aeschlimann and Paulsson, 1994; Lorand 
and Graham, 2003). More recently, TG3 and TG6 have been implicated in extracelluar functions 
(Zone et al., 2011; Thomas et al., 2013). Despite it being 20 years since we first postulated export of 
TGs through an unconventional secretory pathway (Aeschlimann and Paulsson, 1994), the 
underlying process remains elusive. This has gained much attention recently as while matrix 
stabilization by TG2 is required for an effective tissue repair response, aberrant TG2 action has a 
central role in pathogenesis of inflammatory diseases and autoimmunity, most noteably celiac 
disease (Aeschlimann and Thomazy, 2000; Iismaa et al., 2009). Externalization from cells appears 
to control TG2 function as Ca2+-binding serves as a molecular “switch” for its activation, 
facilitating transition into a conformation that enables catalysis (Pinkas et al., 2007). Early studies 
pointed to passive release of TG2 through cell damage (Upchurch et al., 1987; Siegel et al., 2008). 
More recently, several alternative mechanisms for constitutive release of TG2 were proposed, 
including MV shedding (Antonyak et al., 2011; Van den Akker et al., 2011), or perinuclear import 
into Rab11-positive recycling endosomes (Zemskov et al., 2011). However, the proposed 
mechanisms implicated different domains of TG2 (Chou et al., 2011; Zemskov et al., 2011). 
Furthermore, constitutive export is difficult to reconcile with the lack of a correlation between TG2 
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synthesis level and extracellular activity, and the fact that export appears to be cell type or 
differentiation stage specific as exemplified in endochondral bone formation (Aeschlimann et al., 
1995). Such sudden, context-dependent externalization of TG2 indicated that its export is regulated 
by an unidentified signaling event. 
 
One emerging pathway for non-classically secreted proteins including interleukin (IL)-1 
involves P2X7R activation, leading to formation of an inflammasome in a NALP3-dependent 
manner (Dubyak, 2012; Strowig et al., 2012). Inflammasome assembly drives caspase-1 
autoprocessing, maturation of IL-1 by caspase-1 cleavage and ultimately IL-1 release 
(Mariathasan et al., 2006). Activated macrophages derived from P2X7R-/- mice are unable to 
secrete the mature form of IL-1 family cytokines including IL-1β and IL-18 (Solle et al., 2001; 
Pelegrin et al., 2008) and hence, these animals show reduced severity in models of acute 
inflammatory joint or lung disease (Labasi et al., 2002; Lucatelli et al., 2011; Bartlett et al., 2014). 
 
P2X7R is a member of the P2X family of nucleotide gated ion channels that is activated by 
high concentrations of extracellular ATP. Besides K+ efflux that triggers inflammasome assembly, 
the ion channel also supports Ca2+ and Na+ influx, leading to membrane depolarization and 
activation of intracellular signaling cascades (Coddou et al., 2011; Bartlett et al., 2014). The P2X4R 
crystal structure confirmed that assembly of 3 subunits, each harboring two transmembrane 
domains, forms the functional P2X receptor (Kawate et al., 2009). The large extracellular domain 
has ATP and metal ion binding sites that regulate receptor activation state. Channel opening is 
associated with conformational changes that reposition the transmembrane segments whereby 
different states of dilation may be adopted (Hattori and Gouaux, 2012; Jiang et al., 2013). The 
feature that distinguishes P2X7R from the other P2X family members is a long C-terminal tail 
(Suprenant et al., 1996; Rassendren et al., 1997) which has been implicated in the process of 
“membrane pore” formation that enables plasma membrane permeability to larger organic cations 
(Virginio et al., 1999; Browne et al., 2013).   
 
High extracellular ATP is a consequence of cell damage, and enforced by ATP release from 
activated innate immune cells. This acts as a danger signal amplification system that spreads the 
alarm within the local milieu. However, ATP is not only released upon tissue/cell injury or stress, 
but can also be secreted through membrane channels or secretory vesicles (Garcia and Knight, 
2010; Sorge et al., 2012; Burnstock, 2015). Given that TG2 is abundantly secreted in the context of 
inflammation but that extracellular TG2 also has formative roles in tissue development and 
homeostasis, we hypothesized that its export may be associated with P2X7R signaling. Here we Jo
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show for the first time that rapid TG2 export is regulated by P2X7R-mediated membrane pore 
formation.  
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Results 
 
Macrophages secrete TG2 in a P2X7R-dependent manner 
The THP-1 monocyte/macrophage cell model was chosen to investigate TG2 export as these cells 
have been reported to be competent in P2X7R-mediated IL-1β secretion (Mackenzie et al., 2001). 
We confirmed initially that activation of inflammasome formation by priming cells with 
lipopolysaccharide (LPS) for Toll-like receptor (TLR) signaling and subsequent stimulation with 
ATP induces IL-1β secretion into the cell supernatant as determined by capture ELISA (Fig. S1A). 
TG2 is expressed in differentiated macrophages but not in monocyte precursors (Mehta and Lopez-
Berestein, 1986). Therefore, THP-1 cells were treated with the phorbol ester TPA to induce 
differentiation (Fig. S1B), and TG2 upregulation was confirmed by Western blotting of cell lysates 
(Fig. 1A). We then used the ATP analogue BzATP for P2X7R activation as it shows a high degree 
of selectivity for P2X7R and does not activate P2Y family ATP-sensing receptors (Coddou et al., 
2011). Differentiated cells were BzATP stimulated for 10min, and culture supernatants were 
collected at the end of agonist treatment (pulse) and after a further 30min in the absence of agonist 
(chase) to capture immediate and potentially delayed TG2 secretion. BzATP stimulation induced a 
substantial increase in TG2 secretion as determined by Western blotting of cell-free supernatant 
(Fig. 1B). TG2 export was blocked by P2X7R antagonist A740003 (Fig. 1B) that inhibits IL-1β 
secretion in differentiated monocytes (Honore et al., 2006). To substantiate this finding, we 
analysed TG2 secretion in response to P2X7R activation in primary human M1 macrophages. 
BzATP triggered rapid TG2 secretion, contributing to soluble (Fig. 1C) and cell surface associated 
enzyme (Fig. S1C) whereby the soluble enzyme was undergoing processing generating a ~66kDa 
species. Processing did not involve inflammasome-associated caspase-1 nor cell surface MT1-MMP 
cleavage (Belkin et al., 2001) as it occurred in the presence of N-acetyl-YVAD-chloromethyl 
ketone (Ac-YVAD-CMK) or EDTA, respectively (Fig. 1D & S1C). Collectively, these data show 
that P2X7R regulates not only 1L-1 but also TG2 secretion in macrophages.  
 
Expression of P2X7R confers agonist-inducible, rapid TG2 secretion to HEK293 cells  
To investigate whether P2X7R alone was sufficient or other inflammasome pathway components 
are required for TG2 export, we established HEK293 cells stably expressing wildtype or tagged 
human P2X7R. This cell model was selected as it lacks endogenous expression of P2X receptor 
family members (Mackenzie et al., 2005) and secretes mature IL-1 in response to agonist when co-
transfected with P2X7R and pro-caspase-1 (Gudipaty et al., 2003). P2X7R expression was 
confirmed by Western blotting of cell extracts, whereby for tagged P2X7R a single band reactive 
with antibodies to P2X7R and the V5-tag was detected (Fig. S2A). Immunocytochemistry Jo
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confirmed membrane localization of the receptor in P2X7R cells and its absence in parental cells 
(Fig. S2B). In order to assess P2X7R functionality, changes in intracellular free Ca2+ concentration 
in response to BzATP were investigated using Fluo-4-AM. Only P2X7R cells but not parental cells 
responded to this agonist (Fig. S2C). A dose-response analysis for BzATP stimulation of P2X7R 
cells using Ca2+ signaling as a readout derived an apparent KD of ~75M (Fig. S2D). This is in line 
with literature data ranging from 40-100M depending on extracellular Ca2+ concentration 
(Rassendren et al., 1997). Therefore, stimulation with 100M BzATP produced a P2X7R specific 
and in terms of ligand occupancy, relevant response for further investigation of downstream events.  
 
We then investigated whether P2X7R activation induces TG2 secretion. TG2 transfected 
P2X7R cells were treated with agonist for 5, 10 or 30min, followed by a 30min chase period after 
agonist wash out. Supernatants of both fractions were analysed for TG2 by Western blotting. 
Within 10min of BzATP application, pulse fractions revealed substantial TG2 secretion in agonist 
treated but not vehicle treated cells (Fig. 2A). No TG2 export was seen after 5min indicating that 
kinetics were considerably slower than Ca2+ signaling. Interestingly, elevated TG2 levels in the 
chase fraction were observed in cells that were exposed to BzATP for 5min (Fig. 2A) or even 1min 
(not shown), indicating that P2X7R activation and not subsequent events occurring upon prolonged 
agonist exposure triggers TG2 export. As TG2 levels in the chase fraction were agonist exposure 
time independent (Fig. 2A) it appears that once initiated, the TG2 export mechanism is active over 
an extended time period and leads to gradual extracellular TG2 accumulation at a constant rate. 
Note, the amount of secreted TG2 is small compared to the total and hence, export does not deplete 
cellular TG2 over time period investigated (Fig. 2D, cell lysate). To further demonstrate that this 
cell response required P2X7R activity, we employed the competitive P2X7R inhibitor A740003. At 
5M, it completely blocks a rise in [Ca2+]i in response to BzATP (Fig. 2B, top panel), and this is 
reversible upon inhibitor wash out (Fig. 2B, bottom panel). BzATP stimulation of cells in the 
presence of this inhibitor was unable to trigger TG2 secretion (Fig. 2C), demonstrating that active 
secretion of TG2 is a P2X7R regulated process. 
 
P2X7R-mediated TG2 export is not linked to loss of cell membrane integrity or apoptosis 
Shedding of membrane-bound particles containing TG2 together with the lipid raft protein flotillin-
2 was reported (Antonyak et al., 2011). Hence, we investigated whether P2X7R-mediated TG2 
secretion correlated with flotillin-2 release. Western blot analysis of cell lysates confirmed that 
flotillin-2 and TG2 were expressed at comparable levels in P2X7R and parental cells (Fig. 2D, cell 
lysate). Only P2X7R cells responded to BzATP stimulation with release of flotillin-2 into the cell 
supernatant, indicating P2X7R-dependent vesicle shedding (Fig. 2D, medium). Similar to TG2, J
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flotillin-2 was present in the pulse fraction and accumulated in the chase fraction, potentially 
indicating co-release. To further analyse secreted material and exclude protein release through 
passive cell lysis we investigated externalization of the cytosolic proteins IB,  -
tubulin, as well as of HMGB-1 which is secreted non-classically via the exosome pathway (Lu et 
al., 2012). We were unable to detect any of these proteins in the cell supernatant after P2X7R 
activation (Fig. 2E & not shown). However, given that prolonged stimulation of P2X7R can lead to 
cell death (Mackenzie et al., 2005), and this critically affects the conclusions, we designed 
experiments to more selectively investigate loss of membrane integrity and apoptosis, respectively. 
Firstly, release of cytosolic lactate dehydrogenase (LDH) was quantified after stimulation of either 
P2X7R or parental cells with BzATP for 10min. No P2X7R induced release of LDH was seen (Fig. 
S3A). Secondly, BzATP treated P2X7R cells were chased for various times up to 22h and assessed 
for caspase-3 activation by Western blotting. Activated caspase-3 could not be detected at any time 
(Fig. S3B) whereas within 6h of TNF stimulation caspase-3 cleavage was evident as reported 
(Arlt et al., 2003). These data show that TG2 externalization is not related to cell damage or death 
but is a selective process, possibly linked to P2X7R-dependent membrane changes. This is 
consistent with activation of P2X7R triggering rapid alterations in membrane topology without 
causing cell death that completely reverse as [Ca2+]i falls unless receptor stimulation is sustained for 
long time periods (Mackenzie et al., 2005). 
 
TG2 localizes to membrane subdomains upon cell stimulation with P2X7R agonist 
In P2X7R expressing cells, the prolonged increase in [Ca2+]i
 upon BzATP application was followed 
within 30s by extensive cell blebbing as visualized by real-time microscopy (Fig. 3A, arrows). The 
term ‘blebbing’ is used here to describe formation of plasma membrane projections due to Rho-
dependent actin reorganization that follow P2X7R activation (MacKenzie et al., 2001; Pfeiffer et 
al., 2004). This response is P2X specific. Stimulation of the parental cells that express P2Y 
receptors with ATP induced smaller, transient oscillations in [Ca2+]i but no apparent morphological 
changes (Fig. 3A). This led us to speculate that TG2 externalization may be linked to membrane 
bleb formation, and we used GFP-tagged TG2 to monitor its redistribution in live cells. We 
confirmed that P2X7R activation triggered externalization of tagged TG2 similar to wild-type TG2 
(Fig. 3B). Analysis by confocal microscopy revealed a clear ubiquitous cytoplasmic distribution for 
TG2-GFP (Fig. 3C). Upon P2X7R activation, TG2-GFP was rapidly translocating into membrane 
blebs, and freely relocalized to sites where new membrane protrusions formed (Fig. 3C, arrow). 
However, despite abundant bleb formation, careful reconstruction from image sequences revealed 
that these large membrane protrusions remained continuous with the plasma membrane and were 
eventually retracted by cells. We obtained similar results for N- and C-terminally tagged TG2 Jo
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indicating that the position of the tag did not substantially alter protein localization. Although 
unable to directly visualize TG2 release, a noticeable reduction in fluorescence upon P2X7R 
activation indicated that the intracellular pool of TG2 was rapidly diminishing consistent with its 
relocation into the medium (Fig. 3B).  
 
P2X7R agonist-induced TG2 secretion is independent of MV shedding 
As small vesicles may be released by cells that are beyond the resolution of conventional confocal 
microscopy, we used light scattering combined with particle tracking to further analyse cell free 
supernatants for nanoparticles. A robust increase in particle shedding by P2X7R cells upon BzATP 
treatment was observed during stimulation and in the subsequent chase period (Fig. 4A). Most of 
the secreted particles had diameters of 81-262 nm (Fig. 4B) in line with more variably sized MV, 
rather than exosomes that originate from multivesicular bodies, are size-constrained and typically 
<90nm (Cocucci et al., 2009). TG2 expression modestly increased the proportion of larger particles 
(Fig. 4B) but did not significantly alter total particle release (Fig. 4A). To understand if TG2 
localizes in MV, freshly harvested conditioned medium was subjected to differential centrifugation 
and resulting pellets and supernatant were analysed by Western blotting (Fig. 4C). TG2 mainly 
localized to the 100,000xg supernatant fraction containing soluble proteins (S5), with some TG2 
found in very large aggregates or associated with organelles (P2) but not in the MV fraction (P4). 
To substantiate this, MV were separated using a sucrose density gradient (Fig. 4D). Again, TG2 
was predominantly in the soluble protein fraction. These data suggest that while P2X7R activation 
induces abundant MV release by cells, secreted TG2 is not apparently MV-associated but present in 
free form.  
 
Extracellular Ca2+ regulates TG2 externalization but its secretion is independent of catalytic 
enzyme functions 
TG2 secretion was effectively stimulated by P2X7R activation in media that contain 0.9mM Ca2+, 
which is similar to the free ionized extracellular Ca2+ concentration estimated at 1.1-1.3mM 
(Riccardi and Kemp, 2012), but surprisingly not in media containing high Ca2+ (Fig. 1D & 5A). 
BzATP treatment of cells in the absence of Ca2+ lead to enhanced TG2 secretion during stimulation 
only (Fig. 5A), indicating that TG2 export was faster but not sustained. In contrast, flotillin-2 
release occurring at 0.9mM Ca2+ was greatly reduced when cells were stimulated with agonist at 
either 0 or 2.2mM Ca2+ (Fig. 5A). This shows that TG2 and flotillin-2 secretion is differentially 
affected by [Ca2+]ex and hence, that the underlying mechanisms are distinct. As MV shedding is a 
Ca2+-dependent process, TG2 release in Ca2+-free medium supports a vesicle-independent mode of 
release in line with previous data (Fig. 4).  Jo
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To exclude Ca2+-dependent loss of externalized TG2 due to cell surface retention through 
interaction with substrates or autocatalytic crosslinking, we compared secretion of wild-type TG2 
with crosslinking incompetent TG2 C277S (Stephens et al., 2004). BzATP stimulation of cells 
induced export of both TG2 and TG2 C277S at 0.9mM Ca2+ but not at 2.2mM (Fig. 5B). This 
indicates that the lack of TG2 secretion at high [Ca2+]ex is not due to TG2 activity but may reflect 
differences in P2X7R activation state. This is further supported by high [Ca2+]ex affecting flotillin-2 
release as well (Fig 5A). Besides cation transport, activation of P2X7R can lead to “membrane 
pore” formation which manifests as apparent permeability of the plasma membrane to cationic 
molecules such as YO-PRO1 (Virginio et al., 1999; Pelegrín, 2011; Browne et al., 2013). 
Measurement of YO-PRO1 uptake confirmed that P2X7R cells but not parental cells form 
membrane pores upon BzATP treatment (Fig. 5C), and that the dye uptake rate is inversely 
correlated to [Ca2+]ex (Fig. 5D). Ca
2+-nucleotide interactions could potentially limit the effective 
agonist concentration. However, the observed BzATP dose response is not consistent with this 
explanation (Fig. S3C). Therefore, Ca2+ likely acts in our experiments as an allosteric regulator of 
P2X7R, either directly or indirectly inhibiting receptor activation as previously suggested (Yan et 
al., 2011). Taken together, this suggests that high [Ca2+]ex is an important negative regulator of TG2 
secretion, whereby Ca2+ ions appear to regulate P2X7R activation rather than influencing TG2 
activity during export. 
 
TG2 export is linked to P2X7R-mediated membrane pore formation 
To assess the contribution of the initial ion flux on TG2 secretion, calmidazolium was employed. It 
is an inhibitor with broad selectivity for voltage gated fast acting Na+/K+ and L-type Ca2+-channels 
that also inhibits the initial ATP-evoked ion flux through P2X7R without affecting the downstream 
membrane pore formation (Virginio et al., 1997). Calmidazolium has an extracellular mode of 
action on P2X7R. BzATP induced TG2 export in P2X7R cells was unaffected by the presence of 
calmidazolium but flotillin-2 secretion was blocked (Fig. 6A). The inhibitor had no effect on pore 
formation activity of P2X7R (Fig. 6B) but substantially reduced the rise in [Ca2+]i mediated by 
P2X7R activation (Fig. 6C). This indicates that TG2 secretion is linked to P2X7R-dependent pore 
formation but not the initial ion flux and associated membrane depolarization. 
 
Given that TG2 secretion was induced by P2X7R activation in Ca2+-free medium but the 
kinetics of export were altered (Fig. 5A), we investigated whether Ca2+ release from intracellular 
stores plays a role. P2X7R cells were pre-loaded with Ca2+ chelator BAPTA-AM to buffer free 
cytosolic Ca2+ prior to BzATP stimulation in Ca2+-free medium. This reduced TG2 release to near 
baseline levels (Fig. S3D), confirming that Ca2+ signaling has a role in TG2 export as previously Jo
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suggested (Zemskov et al., 2011). Conversely, cyclopiazonic acid (CPA) was applied to inhibit the 
SERCA Ca2+ transporter to trigger a rise in [Ca2+]i in the absence of P2X7R activation. CPA 
addition alone was unable to induce TG2 secretion (Fig. S3D), despite inducing peak [Ca2+]i of the 
same magnitude as P2X7R activation when used at 20M (Fig. S3E). This indicates that a rise in 
[Ca2+]i by itself is not sufficient to induce TG2 export.  
 
TG2 secretion is pannexin independent but enhanced by activating mutations in P2X7R 
P2X7R-mediated membrane pore formation has been proposed to relate to P2X7R channel dilation 
upon saturation of ATP binding sites, possibly combined with acquisition of additional subunits 
(Browne et al., 2013) or alternatively, by coupling to another channel, i.e. pannexin-1 (Pelegrin and 
Suprenant, 2007; Gulbransen et al., 2012). We evaluated the latter by treating cells with pannexin 
inhibitors. Neither the peptidic competitor 10Panx (Pelegrin and Suprenant, 2007) nor trovafloxacin 
(Poon et al., 2014) had any effect on BzATP stimulated YO-PRO1 uptake (Fig. 7A) or TG2 export. 
We therefore sought to clarify whether the C-terminally truncated P2X7R splice variant B that lacks 
pore forming ability (Adinolfi et al., 2010) supports TG2 secretion. However, expression of this 
variant after site-specific stable integration or transient transfection was very low as determined by 
Western blotting of cell lysates (Fig. 7B), and we were unable to confirm cell surface localization 
with P2X7R extracellular domain antibodies. Nevertheless, we attempted to confirm agonist-
mediated membrane depolarization using the sensitive voltage sensing FRET probes CC2-DMPE 
and DiSBAC2 (Wolff et al., 2003). Only wild type P2X7R expressing cells showed membrane 
channel activity (response ratio for P2X7R: 1.53±0.04BzATP, 2.17±0.12KCl, 1.07±0.06control; for 
P2X7R variant B: 1.10±0.03BzATP, 1.74±0.10KCl), suggesting altered trafficking and degradation of 
the truncated receptor variant.  
 
A mutation in mouse P2X7R renders it deficient in pore forming activity (Sorge et al., 
2012). As the affected sequence motif in the P2X7R C-terminal domain is conserved in human, we 
have generated cells expressing human P2X7R with an analogous mutation, P451L (Fig. 7B,C). 
However, these cells formed membrane pores in response to BzATP as revealed by YO-PRO1 
uptake (Fig. 7D). This led us to investigate the gain of function P2X7R variant, A348T, that confers 
increased risk for autoimmune disease in man (Stokes et al., 2010) to substantiate a link between 
pore formation and TG2 secretion. Cells expressing P2X7R A348T (Fig. 7B,C) had a substantially 
increased propensity to form membrane pores as evidenced by enhanced peak pore activity (Fig. 
7D) and by pore formation at very low BzATP concentrations (Fig. 7E). This enhanced pore 
activity was reflected in a corresponding increase in TG2 export (Fig. 7F,G). Interestingly, we also 
observed BzATP-induced secretion of thioredoxin-1 (Fig. 7H), an enzyme that can re-activate Jo
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oxidatively inactivated TG2. This not only indicates that membrane pore activity controls the rate of 
TG2 export but that it leads to co-secretion of TG2 with thioredoxin-1 (Fig. 8). 
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Discussion 
 
We identify P2X7R as the central regulator of the pathway that enables active export of TG2 and its 
co-activator, thioredoxin-1. The action of both of these enzymes has been linked to specific immune 
responses (Ismaa et al., 2009; Jaeger et al., 2013), and this may therefore constitute a pathway for 
export of proteins relevant to innate immunity. Besides having roles in re-instating tissue integrity 
following injury or associated with infection control, TGs including TG2 have been implicated in 
immune regulation (Toth et al., 2009; Loof et al., 2011). Here, we show that in 
monocytes/macrophages, purinergic signaling triggered rapid TG2 export in the absence of TLR 
engagement, and this response was P2X7R dependent but did not require caspase-1 activity. 
Likewise, introduction of P2X7R in HEK293 cells devoid of other inflammasome components (Lu 
et al., 2012) instated agonist-regulated rapid TG2 export. Taken together, the data demonstrate that 
P2X7R signaling alone is sufficient to trigger TG2 export, and involvement of an inflammasome-
independent mechanism of export is further supported by the fact that externalized TG2 was not 
vesicle-associated or co-secreted with exosome-associated HMGB-1.  
 
A redox sensitive Cys switch promotes oxidative inactivation of TG2 (Stamnaes et al., 
2010), a mechanism that is thought to contribute to rapid enzyme inactivation in the extracellular 
milieu (Jin et al., 2011) and thereby, to prevent aberrant crosslinking that may lead to fibrosis and 
potentially autoimmunity via neo-epitope formation (Aeschlimann and Thomazy, 2000; Ismaa et 
al., 2009). However, it has been shown that extracellular matrix-associated TG2 can be reactivated 
by thioredoxin-1 released from activated monocytes in inflammation (Jin et al., 2011). Cell surface 
associated thioredoxin-1 plays a key role in innate immunity, particularly in mucosal epithelia 
where it activates -defensin-1 (Jaeger et al., 2013). Interestingly, thioredoxin-1 is also an 
unconventionally secreted protein (Rubartelli et al., 1992), and our results show that it is in fact co-
secreted with TG2. We speculate that thioredoxin-1 may not primarily act on pre-existing 
extracellular TG2 but may have a role as a chaperone during active TG2 export, enabling 
conversion of TG2 into its active conformation. Such a mechanism could explain why in celiac 
disease active TG2 accumulates in the intestinal mucosa (Korponay-Szabo et al., 2004). 
 
Purinergic signaling fulfills the pre-requisites for a unifying pathway regulating TG export 
As TG2, and also other TGs, can be externalized by a range of cells including myeloid, 
mesenchymal, endothelial and epithelial cells (Aeschlimann and Thomazy, 2000; Nurminskaya and 
Belkin, 2012), it is implausible that this involves multiple highly divergent mechanisms as 
proposed. P2X7R is not restricted to the hematopoietic lineage as originally thought but is also J
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widely distributed among mesenchymal, endothelial and epithelial cells, and in the central and 
peripheral nervous system (Bartlett et al., 2014). Activation of P2X7R occurs not only in 
conjunction with injury, cell stress and inflammatory processes but has major independent roles in 
the musculoskeletal (Garcia and Knight, 2010) and nervous system (Burnstock, 2015), contexts 
within which TG2-mediated extracellular reactions are also prevalent (Aeschlimann et al., 1995; 
Ismaa et al., 2009; Thomas et al., 2013).  
 
Unlike previous work, our data implicate a regulated pathway in TG2 export. This 
mechanism may be activated to a varying extent under different conditions. A key finding here is 
that Ca2+ levels present in many media formulations impair TG2 release. Our data with catalytically 
inactive TG2 C277S show that this is not related to regulation of TG2 by Ca2+ but due to suppressed 
P2X7R functionality in line with evidence suggesting that divalent cations including Ca2+ 
allosterically inhibit P2X7R (Yan et al., 2011). Therefore, varying extracellular Ca2+ or ATP 
concentrations may explain some contradictory findings in the literature. It is worth noting that 
modest shear stress during medium exchange or passaging may trigger cellular ATP release 
(Rumney et al., 2012) and trigger P2X7R-mediated TG2 release at low (0-1mM) but not high 
(≥2mM) [Ca2+]ex. Hence, endogenous P2X7R activation may explain apparently “constitutive” TG2 
secretion.   
 
Crucially, in our HEK293 model TG2 is not retained at the cell surface or internalized, 
unless an appropriate cell surface receptor is introduced (Fig. S4). Hence, TG2 export can be 
directly assessed by quantification in the cell supernatant. Thus, our system is overcoming intrinsic 
difficulties that hampered progress in the analysis of TG2 export previously, including 
quantification of cell surface associated TG2 without disrupting cell integrity or endocytic TG2 
uptake and retrograde transport. This together with modulation of the different P2X7R activities 
with small molecules or by mutagenesis provided strong evidence for a direct link between P2X7R 
signaling and TG2 export. Our data is not contradictory to passive TG2 release as a consequence of 
a substantial insult including mechanical damage (Upchurch et al., 1987) or TLR-engagement 
(Siegel et al., 2008), or to vesicle-associated TG2 release under circumstances such as serum 
starvation-associated cell stress (Antonyak et al., 2011). Rather, it suggests that purinergic signaling 
links controlled TG2 export to specific extracellular functions. Furthermore, given that MV-
associated TG2 co-localized with fibronectin (Antonyak et al., 2011) an extracellular enzyme 
localization is implied. Therefore, it is possible that TG2 preferentially binds to plasma membrane 
subdomains where specific types of MV form (pericellular matrix reorganization) explaining the 
apparent association but that this occurs subsequent to membrane translocation. Jo
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 Different activities of TG2 as well as sequence motifs for interaction with proteins and 
phospholipids were implicated in the export process (Balklava et al., 2002; Scarpellini et al., 2009; 
Chou et al., 2011; Zemskov et al., 2011). Our data show that transamidation activity is dispensable 
for export and that tagging TG2 with GFP does not prevent export, thereby excluding a terminal 
targeting signal. Blocking TG2 interaction with classically secreted proteins such as fibronectin, 
syndecans and integrins may alter extracellular localization or endocytic uptake and trafficking of 
TG2 (Antonyak et al., 2011; Chou et al., 2011; Zemskov et al., 2011) but cannot explain how the 
implied membrane translocation occurs.  
 
Mechanistically, TG2 export is linked to the secondary permeability pathway 
Several lines of evidence show that TG2 export is linked to the “membrane pore” activity 
associated with P2X7R activation (Fig. 8). Our data show that TG2 export is mechanistically 
separate from MV shedding. In line with this, P2X7R induces bleb formation and MV shedding 
through actin reorganization via MAPK p38 and Rho activation whereas YO-PRO1 uptake by cells 
is insensitive to cytochalasin-D (Pfeiffer et al., 2004). We further show that TG2 export is not 
induced by a [Ca2+]i rise alone, nor abrogated by pharmacological suppression of P2X7R ion 
channel function without affecting membrane pore formation. In contrast, introducing a mutation in 
P2X7R that enhanced pore activity resulted in accelerated TG2 export. 
 
P2X7R is the only P2X receptor where membrane pore formation is consistently observed 
and this activity is therefore a defining feature of it. While mechanistically not fully understood, it 
requires the extended unique C-terminal intracellular tail (Smart et al., 2003; Sun et al., 2013). 
Recent data suggest that large cations can pass through the P2X7R channel itself, and that blocking 
the channel prevents dye uptake by cells (Browne et al., 2013). However, a larger channel diameter 
than expected from available structural data (Hattori and Gouaux, 2012) would be required to 
adequately explain permeation of some molecules, and a more substantial conformational change 
than predicted from existing structural data is indeed supported by a recent study (Allsopp and 
Evans, 2015). Interestingly, P2X7R also couples to effectors implicated in dye permeability and a 
sustained [Ca2+]i elevation by itself was shown to trigger membrane pore opening (Bartlett et al., 
2014). In our HEK293 model, calmidazolium attenuated Ca2+ influx while membrane pore activity 
was unaffected suggesting that distinct permeation pathways are involved. Pannexin-1 is not 
involved as shown with inhibitors, consistent with data of others (Sun et al., 2013). Physiologically, 
the secondary permeability pathway may have a role in release of secondary messengers, e.g. 
glutamate release in P2X7R expressing HEK293 cells was reported (Cervetto et al., 2013). Given Jo
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the delay between P2X7R-dependent Ca2+ signaling and detection of changes in extracellular TG2, 
we cannot exclude a role of a secondary messenger system. However, it is conceivable that this 
pathway constitutes a pore through which proteins can be trafficked via co-translocational 
unfolding (Rodriguez-Larrea and Bayley, 2014). 
 
TG2 activation is biological context-dependent 
Given its requirement for high extracellular ATP concentration, P2X7R will primarily be activated 
after injury, in the context of inflammation, or in the tumor microenvironment. Enhanced TG2 
expression by resident fibroblasts and infiltrating myeloid cells is an integral part of the tissue repair 
response and leads to accumulation of extracellular TG2. TG2 secretion is thought to bring about its 
activation via Ca2+-induced conformational changes (Pinkas et al., 2007). However, it is possible 
that high extracellular nucleotide concentrations at sites of injury or inflammation not only activate 
P2X7R itself but also control TG2 activation as purine nucleotides are allosteric inhibitors, although 
the apparent binding affinity for ATP is low (~1mM) compared to GTP (~3M) (Han et al., 2010; 
Thomas et al., 2013). Furthermore, a proposed heparan sulfate binding site is unique to the GTP-
induced conformation (Lortat-Jacob et al., 2012) and such an interaction may stabilize this 
conformation and prevent Ca2+ binding. Therefore, it is worth noting that signaling functions for 
extracellular nucleotide bound enzyme have been postulated (Johnson and Terkeltaub, 2005; Toth 
et al., 2009).  
 
Implications for TG2-mediated disease processes  
P2X7R is highly polymorphic, and it has become increasingly clear that some amino acid 
substitutions predispose to disease (Bartlett et al., 2014). We have shown here that a polymorphism 
in the second transmembrane domain that is associated with autoimmune disease (Stokes et al., 
2010) facilitates membrane pore formation leading to enhanced TG2 secretion. This opens the 
possibility that the threshold for activation of TG2 export differs between individuals depending on 
their P2RX7 genotype, and this may constitute a risk factor for diseases where TG2 mediated 
reactions cause pathology. This extends to animal models of disease. Notably, in contrast to mouse 
strain 129, the C57BL/6 background widely used in genetic studies carries P2X7R P451L which 
lacks the capacity to form membrane pores (Sorge et al., 2012). Different mouse lines may 
therefore differ with regards to the capacity for active TG2 export.  
 
In conclusion, we have demonstrated that TG2 export is regulated by purinergic signaling, 
and that P2X7R plays a central role in this process. Our findings provide an explanation for the link 
between high levels of extracellular TG2 activity and inflammatory responses, and thereby identify Jo
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a new avenue to limit TG2 activity therapeutically in conditions where enzyme function directly 
drives pathogenic processes including fibrotic disease and gluten related disorders. 
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Materials and methods 
Cell culture  
THP-1 monocytic leukemia cells were grown in suspension in RPMI1640 medium containing 10% 
heat inactivated FBS, streptomycin, and penicillin. Mononuclear cells were isolated from 
heparinised human blood on Ficoll-Plaque PREMIUM (GE Healthcare), washed in PBS, and 
cultured for 7 days as THP-1 cells but with addition of 20ng/ml human GM-CSF (Preprotech) to 
derive M1 macrophages (with informed consent of donors and approval of the Research Ethics 
Committees: REC10/MRE09/28). HEK293 flp-in cells (Invitrogen) were cultured in DMEM 
containing 10% FBS, above antibiotics and 100g/ml zeocin (Invitrogen). Experiments were 
conducted without antibiotics. 
 
Generation of stably transfected cell lines 
P2X7R was amplified by PCR from image clone (ID:4298811) using primers specified in Table S1 
to generate wild-type, truncated and V5-tagged coding sequences, which were cloned into 
pcDNA5/V5-His/FRT vector (Invitrogen). Constructs for P2X7R mutants were generated by site 
directed mutagenesis using oligonucleotides given in Table S1. The coding sequence of all 
constructs was verified by sequencing. Cell lines were generated by co-transfection of P2X7R and 
recombinase (pOG44, Invitrogen) expression vectors into HEK293 flp-in cells using FuGENE 6 
(Promega), followed by selection of stable transfectants with hygromycin B (100g/ml).  
 
THP-1 cell differentiation and activation  
Cells were differentiated with 0.5g/ml TPA, and for IL-1 upregulation, treated with 100ng/ml 
LPS for 24h. For activation, cells (1x106/well) were suspended in PSS (10mM Hepes/NaOH, pH 
7.4, 147mM NaCl, 2mM KCl, 1mM MgCl2, indicated CaCl2 concentration, and 12mM glucose) 
and ATP stimulated. Medium was carefully collected and rendered cell-free by centrifugation 
(1,500xg, 10min). Cells were extracted on ice in 20mM Hepes/NaOH, pH 7.4, 150mM NaCl, 1mM 
EGTA, 1% Triton-X100, 0.25% deoxycholate, 10% glycerol, 1mM PMSF and 1mM N-
ethylmaleimide, and the extract cleared by centrifugation (15,000xg, 10min, 4˚C). IL-1 
concentration in conditioned media (100l) was determined by capture ELISA (Ready-SET-Go Set, 
eBioscience). 
  
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
dv
an
ce
 a
rt
ic
le
 Immunocytochemistry 
Cells grown on poly-L-lysine coated coverslips were fixed with 2% paraformaldehyde/PBS for 
10min, and permeabilized in 0.1% Triton-X100/PBS. After blocking of non-specific binding with 
1% BSA/PBS, P2X7R was detected with 2g/ml anti-P2X7R antibodies (sc-25698, Santa-Cruz) 
and Alexa Fluor 488-conjugated secondary antibodies. Coverslips were mounted using Vectashield 
containing DAPI. 
 
[Ca2+]i measurements in individual cells 
Fluo-4-AM (Invitrogen) Ca2+ indicator was prepared in DMSO containing 20% Pluronic F-127. 
Cells (7x104/well) in poly-L-lysine coated glass bottom dishes (50mm; MatTek) were loaded for 
20min with 3M Fluo-4-AM in OptiMEM (Invitrogen). Medium was replaced with fresh 
OptiMEM, and cells were monitored by confocal microscopy during ATP or BzATP (Sigma) 
stimulation at 37˚C/5% CO2. Real-time videos were acquired (2.62s/frame, 63x objective) using 
sequential scanning. For experiments with P2X7R antagonist, cells were Fluo-4-AM loaded in 
OptiMEM containing 5M A740003 (Tocris) prior to stimulation with agonist in A740003-
containing OptiMEM. Images were analyzed using the LAS-AF software (Leica). 
 
Analysis of TG2 externalization 
Differentiated THP-1 cells (1x106/well) and primary macrophages (1x105/well, 24-well plates) were 
stimulated with P2X7R agonists in OptiMEM. HEK293 P2X7R or parental cells (1.5x105/well, 24-
well plates) were transfected with 0.5g expression construct for wild-type TG2 or TG2 C277S 
(Stephens et al., 2004), or GFP-tagged TG2 (Table S2) using FuGENE-6. After 48h, cells were 
washed with pre-warmed/gassed OptiMEM, and stimulated with P2X7R agonist or CPA (Merck-
Millipore) in OptiMEM (250l/well). For inhibitor studies, cells were treated with 5M A740003, 
1M calmidazolium chloride (Merck-Millipore), 10M BAPTA-AM (Merck-Millipore) or vehicle 
for 10min, and then BzATP stimulated in presence of respective inhibitors as indicated. Caspase-1 
inhibitor Ac-YVAD-CMK was prepared fresh in OptiMEM and diluted to 100M final 
concentration in experiments. Cell supernatant (pulse fraction) was collected, and cells washed with 
and subsequently incubated in pre-warmed/gassed OptiMEM without agonist for 30min (chase 
fraction). Conditioned media from four wells (six wells for macrophages) were combined, and 
rendered cell-free by centrifugation (1,500xg, 10min) for analysis. Cell surface protein labeling 
with Sulfo-NHS-SS-biotin and purification was carried out with the Pierce cell surface protein 
isolation kit. 
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Immunoblotting 
Lyophilized (500l) or ethanol precipitated (1.3ml, macrophages) conditioned media were 
reconstituted in 1/10th or 1/50th of original volume of 12.5mM Tris/HCl, pH 6.8, 4M urea, 2% SDS, 
20mM EDTA, 2% -mercaptoethanol, and 15% glycerol. Protein concentrations of extracts were 
determined with Bicinchoninic Acid Protein Assay. 20l reconstituted media or 10g cell extract 
together with Amersham LMW-SDS markers were separated on 4-20% SDS-PAGE Tris/glycine 
gels (Invitrogen) under reducing conditions, and transferred onto nitrocellulose membranes. For 
thioredoxin-1 detection, ethanol precipitated (1:9,v/v) proteins (600l medium) were resuspended 
as above, and separated in 16% SDS-PAGE Tricine gels (Invitrogen) calibrated with Broad Range 
marker (11-190kD; NEB). Antibody labeling was performed as described (Aeschlimann et al., 
1993) using monoclonal CUB7402 to TG2 (0.2g/ml), TUB2.1 to -tubulin (2.6g/ml), to flotillin-
2 (0.5g/ml; 610383, BD-Biosciences), to HMGB-1 (0.73g/ml; ab184203, Abcam), to V5-tag 
(20ng/ml) or polyclonal anti-IB (1g/ml; sc-371, Santa-Cruz), anti-caspase-3 (40ng/ml; 9662, 
Cell-Signaling), anti-P2X7R C-terminus (1g/ml) or anti-P2X7R extracellular domain (1.7g/ml; 
APR-008, Alomone Labs) antibodies. Anti-thioredoxin-1 antibodies (1:200; FL105, Santa-Cruz) 
were used with 5% casein as blocking agent. Bound antibodies were detected with HRP-conjugated 
secondary antibodies and Amersham ECLTM Plus/Prime. TG2 band intensity was quantified by 
densitometry using Image Lab 5.1 software (Bio-Rad). 
 
Analysis of cell damage and apoptosis 
To assess cell integrity, LDH release was measured using CytoTox-ONETM HMI Assay (Promega). 
Cells (1.2x105/well, 24-well plate) were BzATP-treated in 300l OptiMEM for 10min (n=4), and 
cell-free conditioned media (100l) analyzed for LDH. For estimation of total LDH, a replicate well 
set was subjected to cell lysis.  
To assess whether treatment induced cell death, P2X7R cells were BzATP stimulated and 
chased as described, and where indicated subsequently cultured in serum containing DMEM for up 
to 22h. Cell extracts and particulate material recovered from conditioned media were analysed for 
caspase-3 by immunoblotting. 
 
Localization of GFP-tagged TG2 using confocal microscopy 
P2X7R cells on poly-L-lysine coated coverslips were transfected with constructs for expression of 
N- or C-terminally GFP-tagged TG2. After 24h, the coverslip was mounted for microscopy into a 
customized holder using silicone grease. Cells were kept in OptiMEM at 37˚C/5% CO2, and 
stimulated with a defined volume of agonist solution to obtain 1mM ATP or 100M BzATP while 
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monitoring GFP fluorescence and acquiring real-time movies. 
 
Detection and isolation of MV  
TG2 or mock transfected P2X7R cells were stimulated with 100M BzATP or vehicle. Freshly 
collected conditioned media were rendered cell-free by centrifugation (1,500xg, 10min) and 
supernatants analysed for MV by particle tracking using the NanoSight LM12 system with a high 
sensitivity camera (Webber and Clayton, 2013). Five 60s videos per sample (1-5x108 particles/ml) 
were recorded at 25.6 frames/s (gain=250), and analysed using the NTA2.3 software. Alternatively, 
freshly collected conditioned media were subjected to differential centrifugation at 4˚C, with 
1,500xg for 10min, followed by 3,000xg for 20min, and then either 10,000xg for 30min and 
100,000xg for 1h or subjected to density gradient centrifugation. Supernatant (1.0 ml) was carefully 
layered on Tris-buffered sucrose step gradient (0/20/60%) and centrifuged at 100,000xg for 90min. 
Fractions (~1ml) constituting top layer and 20/60% interface (MV fraction) as well as pellet were 
collected. Proteins were precipitated with 9 volumes of ethanol at 4˚C, and analysed using 
immunoblotting.  
 
P2X7R “membrane pore” activity 
Cells in poly-L-lysine coated black optical 96-well plates (Nunc, 165305) were placed in PSS 
containing 0-2mM Ca2+ and 1M YO-PRO1 (Invitrogen). The plate was transferred to a FLUOstar 
Omega reader (BMG Labtech) equilibrated to 37˚C/5% CO2. BzATP was injected to obtain 0-
500M final concentration (n=3) and fluorescence measured (4mm orbital area) every 40s for 
30min. Where indicated, cells were preincubated with 100M 10Panx (Tocris) for 10min or 10-
100g/ml trovafloxacin (Sigma) for 30min and stimulated in the presence of inhibitors. After 
normalization for well-specific fluorescence, average YO-PRO1 fluorescence of unstimulated cells 
was subtracted from that of agonist stimulated cells to correct for bleaching. Dye uptake rates were 
derived by linear regression of data from initial 5min. 
 
[Ca2+]i measurements in plate format 
Cells (3x104 /well) in optical 96-well plates were loaded with Fluo-4-AM, washed, and placed in 
fresh OptiMEM (90l/well). After measuring baseline fluorescence, different concentrations of 
BzATP (0-300M) or medium alone were injected (10l/well). Fluorescence changes were 
measured in well mode over 20s, with 40 0.1s intervals followed by 0.4s intervals. Data from eight 
wells per condition were averaged. Fluorescence of control was subtracted from data with agonist 
treatment to correct for bleaching. Data (F=fluorescence, t=time) for the first 10s were fitted using 
equation 1 to estimate the maximal fluorescence value (Fmax):   
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 𝐹 =
1−𝑒−(𝐴−𝐹𝑚𝑎𝑥)𝑘𝑡
1
𝐹𝑚𝑎𝑥
 – 
1
𝐴
𝑒−(𝐴−𝐹𝑚𝑎𝑥)𝑘𝑡
+ 𝐶 (1) 
 
whereby k is the association constant, A is a function of agonist concentration and C is a constant 
for baseline correction. The association constant obtained from data fitting was k=1.8x10-6M-1s-1. 
Fmax was then plotted against the agonist concentration to derive a dose-response curve.   
 
Membrane potential analysis  
Voltage sensor probes, coumarin-labeled phospholipid CC2-DMPE (FRET donor) and oxonol dye 
DiSBAC2(3) (acceptor), were from Invitrogen. Cells (3x10
4/well) in optical 96-well plates were 
loaded with 10M CC2-DMPE in FRET buffer (10mM Hepes/NaOH, pH 7.4, 160mM NaCl, 
0.9mM CaCl2, 1mM MgCl2, and 10mM glucose) containing 200g/ml Pluronic F-127 for 30min, 
washed, and incubated in 100l 10M DiSBAC2(3) in FRET buffer for 20min. 10min after addition 
of tartrazine (1.2mM), fluorescence measurements (Ex420-10nm, Em=460-10nm/550-10nm) were 
conducted in well mode at 37˚C/5% CO2. Gain was adjusted to yield similar baseline readings for 
each fluorophor at resting potential. Following baseline acquisition, 10l 0.82M KCl, 100M 
BzATP, or buffer control were injected while monitoring fluorescence. Following subtraction of 
signal without cells, the signal ratio (SR) before and at equilibrium after depolarization was 
calculated, and the response ratio (RR) derived: RR=SRdepol/SRpol.   
 
Statistics 
One-way ANOVA was used and significance between groups determined with Tukey post-test, 
whereby p < 0.05 was considered significant. 
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Ac-YVAD-CMK, N-acetyl-YVAD-chloromethyl ketone; 
BAPTA-AM, (1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid) acetoxymethylester; 
BzATP, benzoylbenzoyl-ATP; 
CPA, cyclopiazonic acid; 
Fluo-4-AM, Fluo-4 acetoxymethylester; 
HMGB-1, high-mobility group box protein-1; 
IB, nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor alpha; 
IL, interleukin; 
LDH, lactate dehydrogenase; 
LPS, lipopolysaccharide; 
MV, microvesicles; 
NALP, NACHT domain-, leucine-rich repeat-, and PYD-containing protein; 
P2X, purinergic receptor (ion channel); 
P2X7R, P2 receptor X7; 
P2Y, purinergic receptor (G-protein coupled); 
PSS, physiological salt solution; 
SERCA, Sarco(Endo)plasmic reticulum Ca2+ ATPase; 
TG, transglutaminase; 
TLR, Toll-like receptor; 
TPA, 12-o-tetradecanoyl-phorbol-13-acetate. 
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Figures 
 
 
 
Fig. 1   P2X7R inhibition blocks TG2 secretion by macrophages. 
(A) Differentiated monocytes express TG2. THP-1 cells were differentiated for indicated time with 
TPA and stimulated with LPS as indicated. Cell extracts were analysed by Western blotting for 
TG2, or -tubulin as a loading control (*=non-specific reactivity).  
(B) TG2 export requires P2X7R activity. Differentiated THP-1 cells were pre-treated with vehicle 
or 5μM P2X7R inhibitor A740003 for 10min, then stimulated as indicated with BzATP for 10min 
with or without inhibitor (pulse). Cells were chased for 30min in P2X7R agonist/antagonist-free 
medium. Collected media of pulse and chase (200l) were rendered cell-free by centrifugation, and 
analyzed for TG2 by Western blotting.  
(C,D) P2X7R activation triggers TG2 secretion in peripheral blood mononuclear cell-derived 
macrophages. Macrophages were BzATP stimulated and chased as in B, and collected media of 
pulse and chase analyzed for TG2 by Western blotting alongside the cell lysates (C). The presence 
of 100M Ac-YVAD-CMK did not prevent externalization or cleavage of TG2, indicating a 
caspase-1 independent process (D). 
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Fig. 2   P2X7R activation mediates TG2 externalization. 
(A) Analysis of TG2 secretion in HEK293 P2X7R cells. TG2 transfected cells were stimulated with 
BzATP or vehicle for indicated time (pulse), then incubated for 30min in agonist-free medium 
(chase). TG2 secretion into cell-free supernatants was assessed by Western blotting. 
(B) Inhibitor A740003 reversibly blocks P2X7R activation. P2X7R cells were incubated with Fluo-
4-AM and 5μM P2X7R inhibitor for 20min prior to BzATP stimulation in the presence of inhibitor Jo
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(top), washed with inhibitor-free medium for 5min, and then re-stimulated with BzATP (bottom). 
Fluorescence (Ex=488nm, Em=500-535nm) change in individual cells was monitored by confocal 
microscopy (mean±s.e.m., n=30) (right). Optical sections of the same field before and 180s after 
BzATP addition are shown (left). Bar=25m.  
(C) P2X7R inhibitor blocks TG2 secretion. TG2 transfected P2X7R cells were pre-treated with 
P2X7R inhibitor or vehicle for 10 min before BzATP stimulation as indicated. TG2 release into 
media was assessed as in A.  
(D,E) Cells release membrane-bound particles upon P2X7R activation. TG2 transfected P2X7R or 
parental cells were BzATP stimulated for 10min, and chased in agonist-free medium. Conditioned 
media and cell lysate were analysed by Western blotting for TG2 and the MV marker flotillin-2 (D) 
or as a control, -tubulin, IB and HMGB-1 (E). 
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Fig. 3   Membrane blebs induced by P2X7R activation contain TG2. 
(A) P2X7R signaling induces rapid membrane blebbing. Fluo-4-AM loaded P2X7R cells were 
stimulated with BzATP while acquiring fluorescence and phase contrast images by real-time 
microscopy to visualize morphological changes and Ca2+ signaling simultaneously (top). Membrane 
blebs are indicated by arrows. ATP stimulation of parental cells induces oscillating Ca2+ signals but 
no overt morphological changes (bottom). Bar=25m. 
(B,C) TG2 redistributes into membrane blebs. To confirm export of tagged TG2, TG2 (WT) or 
TG2-GFP expressing P2X7R cells were stimulated with 100M BzATP for 10min, chased for J
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30min in agonist-free medium, followed by analysis of conditioned media and cell extracts for TG2 
by Western blotting (B). To localize GFP-tagged TG2 during BzATP stimulation, real-time 
confocal microscopy was employed. Genesis of a membrane bleb is depicted (arrow), with an 
optical section of GFP fluorescence overlaid onto phase contrast images to correlate morphological 
changes with changes in TG2 distribution (C). Bar=25m. 
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Fig. 4   P2X7R-mediated TG2 export is not due to MV release. 
(A,B) Analysis of vesicle release by nanoparticle tracking. TG2 or mock transfected P2X7R cells 
were BzATP stimulated for 10min, chased for 30min in agonist-free medium, and conditioned 
media analysed for nanoparticles using light scattering in combination with particle tracking 
(Nanosight). Particle distribution and total particle concentration is shown (mean±s.e.m.; n=5) (A). 
Particles were broadly assigned to 4 fractions based on volume:  representing exosomes (~60nm; Jo
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≤80nm diameter), MV (~145nm; 81-262nm), larger vesicles (~335nm; 263-425nm) and 
aggregates/membrane blebs (≥426nm) (B). 
(C,D) Analysis of isolated MV for TG2. Cell-free media (S1) of BzATP or control treated cells 
were subjected to differential centrifugation (P=pellet; S=supernatant): in C, 3000xg twice (P2, P3), 
10,000xg (P4), and 100,000xg (P5, S5) and in D, 3,000xg followed by separation of MV on a 
sucrose cushion, and fractions analysed for TG2 by Western blotting. 
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Fig. 5   Extracellular Ca2+ regulates TG2 secretion. 
(A) P2X7R-mediated TG2 export at different [Ca2+]ex. P2X7R cells expressing TG2 were BzATP 
stimulated for 10min in medium containing 0.9 or 2.2mM Ca2+ or in Ca2+-free medium, and chased 
for 30min in respective media without BzATP. Conditioned media were analyzed by Western 
blotting for TG2 and flotillin-2.  
(B) TG2 catalytic activity is not required for P2X7R-mediated export. P2X7R cells expressing TG2 
or TG2 C277S mutant were BzATP stimulated in medium containing 0.9 or 2.2mM Ca2+ and TG2 
export was assessed as above.  
(C,D) [Ca2+]ex regulates P2X7R activity. P2X7R or parental cells were stimulated with BzATP as 
indicated in PSS containing YO-PRO1 and different concentrations of Ca2+. To determine YO-
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PRO1 uptake by cells after BzATP application, changes in well-specific fluorescence (Ex=480-
10nm, Em=520-10nm) were monitored over time. A representative experiment of dye uptake in 
Ca2+-free PSS is shown as mean±s.e.m. of 2 wells (C). In D, the initial rates of YO-PRO1 uptake at 
different [Ca2+]ex in response to 300μM BzATP are given (mean±s.e.m.; n=2).  
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Fig. 6   TG2 export is independent of K+ efflux and membrane depolarization.  
(A) Calmidazolium (calm) blocks flotillin-2 but not TG2 release. TG2 transfected P2X7R cells 
were pre-treated for 10min and then BzATP stimulated in medium containing 1M calm or vehicle. 
Cells were chased in agonist-free medium, and conditioned media analyzed by Western blotting for 
TG2 and flotillin-2.  
(B) Calm does not affect P2X7R-dependent “membrane pore” formation. P2X7R cells were pre-
treated with calm, P2X7R inhibitor A740003 or vehicle for 10min prior to stimulation with 100M 
BzATP in the presence of respective inhibitors or carrier in PSS containing YO-PRO1 and 0.9mM 
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Ca2+. Dye uptake was monitored over time. Results are shown as mean±s.e.m. of 2 wells, and is 
representative of 3 independent experiments.  
(C) Calm ameliorates large rise in [Ca2+]i. Fluo-4-AM loaded P2X7R cells were pre-treated with 
calm, P2X7R inhibitor or vehicle for 20min prior to stimulation with 100μM BzATP in the 
presence of inhibitors or carrier. Fluorescence change (Ex=485-12nm, Em=520-10nm) relative to 
control in response to agonist treatment was monitored (mean±s.e.m. of 8 replicate wells).  
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Fig. 7   P2X7R-mediated membrane pore formation is required for TG2 externalization. 
(A) P2X7R-mediated pore formation is pannexin independent. P2X7R cells were pre-treated with 
10Panx or trovafloxacin (Trova) as indicated, and then BzATP stimulated in PSS with respective Jo
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inhibitors, YO-PRO1 and 0.9mM Ca2+. Results are given as initial rates of dye uptake relative to 
control. Pannexin inhibitors did not affect dye uptake, neither at limiting nor saturating agonist 
concentration. 
(B,C) Characterization of expression of mutant P2X7Rs. Extracts of cells stably expressing 
wildtype (wt), A348T or P451L P2X7R, or P2X7R variant B (varB) were analysed by Western 
blotting with antibodies to P2X7R extracellular domain, and to β-tubulin as a loading control (B). 
Membrane localization of receptor was confirmed by immunocytochemistry (C; compare to Fig. 
S2B). Images reflect an optical section acquired by confocal microscopy. Bar=12.5m. 
(D,E) Pore formation is enhanced in cells expressing P2X7R A348T. YO-PRO1 uptake following 
stimulation of cells with 100M BzATP is shown as mean fluorescence±s.e.m. (D). Comparison of 
initial rate of YO-PRO1 uptake for P2X7R A348T and P451L expressing cells highlights increased 
pore activity for P2X7R A348T but unchanged ligand regulation (E). 
(F-H) TG2 export correlates with receptor pore activity. TG2 transfected cells expressing P2X7R 
variants were BzATP stimulated for 10 min, and chased in agonist-free medium. Conditioned media 
were analyzed by Western blotting for TG2 (F), and results (n=3) quantified by densitometry (G). 
Note, cell lysates confirm comparable TG2 expression levels in different cell lines (F). For 
thioredoxin-1 (Trx) detection, media (P2X7R cells) were analysed by Western blotting after 
separation in 16% SDS-PAGE Tricine gels (H).  
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Fig. 8   Mechanism controlling TG2 export.  
Schematic showing different events occurring upon P2X7R activation by ATP. (A) Ion channel 
activity triggers intracellular signaling that results in actin reorganization and MV shedding. 
However, these MV do not contain TG2. (B) Coupling between P2X7R and pannexin-1 triggers 
hemichannel pore opening. TG2 secretion was unaffected by blocking pannexin-1 channels. (C) 
P2X7R itself can form a membrane pore through conformational changes and possibly receptor 
oligomerization in a process that involves the extended intracellular C-terminal sequence. TG2 
secretion is associated with this membrane pore activity but independent of ion channel function, 
and occurs in conjunction with thioredoxin-1 externalization. As thioredoxin can reactivate TG2 
functionally blocked in an oxidized state, this may ensure that externalized TG2 has transamidation 
activity. 
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